EUCTR2010-022620-77-FR进行中（未招募）1 期
A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with etoposide, or masitinib in combination with irinotecan in patients with advanced hepatocellular carcinoma and who relapsed after a first line therapy with sorafenib.
AB Science0 个研究点目标入组 36 人开始时间: 2010年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Patient with histologically or cytologically confirmed advanced-stage hepatocellular carcinoma (HCC) (unresectable, and/or metastatic) or responding to the Barcelona diagnostic criteria
- •2.Patient who have discontinued from first line treatment with sorafenib monotherapy for any reason (ie, tumor disease progression, intolerance) at least 14 days prior to planned randomization but have not received any second line treatment for HCC
- •3.Patient who have recovered from any significant sorafenib-related treatment toxicities prior to randomization (=Grade 2)
- •4.Patient with at least one untreated target lesion that could be measured in one dimension, according to the Response Evaluation Criteria in Solid Tumors (RECIST)
- •5.Patients who have received local therapy prior to sorafenib administration (radiation, surgery, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection [PEI] or cryoablation) are eligible. Local therapy must be completed at least 4 weeks prior to the baseline scan
- •6.Adequate antiviral systemic therapy in sympotomatic and asymptomatic HBV Ag carriers
- •7.Patient eligible for receiving a second line treatment including etoposide and irinotecan
- •8.Child-Pugh liver function class A
- •9.Barcelona Clinic Liver Cancer (BCLC) classification: class C
- •10.Eastern Cooperative Oncology Group (ECOG) Performance Status = 2
- •11.Patient with adequate organ function:
- •Absolute Neutrophil Count (ANC) = 1.5 x 109/L
- •Haemoglobin = 10 g/dL
- •Platelets (PTL) = 85 x 109/L
- •AST/ALT = 5 x ULN
- •Gamma-GT = 5 x ULN
- •Bilirubin = 1.5 x ULN
- •Creatinin clearance = 50 mL/min (Cockcroft and Gault formula)
- •Albumin > LLN
- •Urea = 2 x ULN
- •Proteinuria < 30 mg/dL; in case of proteinuria = 30 mg/dL on the dipstick, 24 hours proteinuria < 1.5g/24 hours
- •12.Patient with life expectancy = 3 months
- •13.Female or male patient = 18 years
- •14.Patient weight > 40 kg and BMI > 18
- •15.Female patient of child bearing potential who agrees to use a method of medically acceptable forms of contraception during the study and 3 months after the last intake of study treatment
- •16.Patient able and willing to comply with study visits and procedures as per protocol
- •17.Patient able to understand, sign, and date the written informed consent form at the screening visit prior to any protocol-specific procedures are performed
- •18.Patient affiliated to a social security regimen
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patient intolerant to etoposide or irinotecan
- •2.Patient who have received a liver transplant
- •3.Patient with clinically significant symptoms of hepatic encephalopathy
- •4.Patient who have received a previous systemic therapy (including investigational agents) other than sorafenib (see Inclusion Criterion 2) for treatment of HCC. Patients participating in surveys or observational studies are eligible to participate in this study
- •5.Patient who have had treatment with any of the following within the specified timeframe prior to randomization:
- •Any sorafenib within the 14 days prior to randomization
- •Major surgery within the 4 weeks prior to randomization
- •Any transfusion, treatment with blood component preparation, received erythropoietin , albumin preparation, and granulocyte colony-stimulating factor (G CSF) within the 2 weeks prior to randomization
- •6.Patient with previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T1). Any cancer curatively treated > 3 years prior to entry is permitted
- •7.Patient presenting with at least one of the following condition:
- •-Ischemic heart disease, defined by at least one of the following condition:
- •a.Medical history of ischemic heart disease
- •b.Clinical symptoms of ischemic heart disease
- •c.Q wave > 3 mm on the electrocardiogram
- •d.ST elevation or depression > 2 mm on the electrocardiogram
- •e.Negative T wave in at least 2 leads of the electrocardiogram
- •-Cardiac failure, defined by at least one of the following condition:
- •a.Medical history of cardiac failure defined by a previous left ventricular ejection fraction = 50%
- •b.Clinical symptoms of cardiac failure
- •c.Current treatment for cardiac failure
- •d.NT Pro-BNP = 300 pg/mL or BNP = 75 pg/mL and/or troponin T > 0.1 ng/mL or troponin I > 0.35 ng/mL
- •-Conduction disorders or arrhythmia, defined by at least one of the following and confirmed by electrocardiogram:
- •a.Severe ventricular arrhythmia (frequent premature ventricular beats)
- •b.Atrioventricular block at second or third level
- •c.Left bundle branch block
- •8.Pregnant or nursing female patient
- •9.Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
- •10.Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent.
- •Previous treatment
- •11.Patient treated with any investigational agent within 4 weeks prior baseline
研究者
相似试验
进行中（未招募）
1 期
Evaluation of safety and efficacy of masitinib combined with etoposide or irinotecan in patients with relapsing liver cancerMedDRA version: 18.1 Level: LLT Classification code 10019829 Term: Hepatocellular carcinoma recurrent System Organ Class: 100000004864MedDRA version: 18.1 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864MedDRA version: 18.1 Level: LLT Classification code 10019830 Term: Hepatocellular carcinoma resectable System Organ Class: 100000004864Hepatocellular carcinomaEUCTR2010-022620-77-GRAB Science34
进行中（未招募）
1 期
Evaluation of safety and efficacy of masitinib combined with etoposide or irinotecan in patients with relapsing liver cancerHepatocellular carcinomaMedDRA version: 17.1 Level: LLT Classification code 10019829 Term: Hepatocellular carcinoma recurrent System Organ Class: 100000004864MedDRA version: 17.1 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864MedDRA version: 17.1 Level: LLT Classification code 10019830 Term: Hepatocellular carcinoma resectable System Organ Class: 100000004864EUCTR2010-022620-77-SKAB Science36
进行中（未招募）
1 期
Evaluation of safety and efficacy of masitinib combined with etoposide or irinotecan in patients with relapsing liver cancerMedDRA version: 20.0Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableSystem Organ Class: 100000004864Hepatocellular carcinomaEUCTR2010-022620-77-CZAB Science36
进行中（未招募）
1 期
Evaluation of safety and efficacy of masitinib combined with etoposide or irinotecan in patients with relapsing liver cancerHepatocellular carcinomaEUCTR2010-022620-77-ESAB Science36
进行中（未招募）
1 期
A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate the efficacy and safety of masitinib in combination with 5-fluorouracil (5-FU) or capecitabine, or masitinib in combination with irinotecan, or masitinib in combination with irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI protocol), as second line chemotherapy in patients with gastric or gastro-oesophageal junction metastatic adenocarcinoma.gastric or gastro-oesophageal junction metastatic adenocarcinomaMedDRA version: 12.1 Level: PT Classification code 10063916 Term: Metastatic gastric cancerMedDRA version: 12.1 Level: PT Classification code 10062878 Term: Gastrooesophageal cancerEUCTR2010-022793-14-FRAB Science57